Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

PINCLUS Chaotropic transmembrane delivery of proteins

Coordinator
Universidad De Santiago De Compostela, Spain
Runs
1 August 2027 to 31 July 2029
Status
Running
EU funding
€194k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101277810

What the project is doing

In the project's own words, from its summary on CORDIS.

Protein biologics hold immense therapeutic promise, yet their clinical potential is constrained by a fundamental barrier: the cellular membrane. While several protein-based drugs have achieved clinical success, they remain limited to extracellular targets. Unlocking intracellular access would dramatically expand the therapeutic scope of protein drugs, enabling intervention at previously inaccessible disease sites. Current intracellular delivery strategies rely on physical or amphiphilic mechanisms, both of which suffer from critical drawbacks including cytotoxicity, cargo aggregation, and endosomal entrapment.

PINCLUS proposes a transformative alternative by leveraging super-chaotropic boron clusters as transmembrane carriers. These inorganic, doubly anionic, water-soluble clusters bypass endosomal pathways and avoid aggregation or membrane disruption, offering a biocompatible route for intracellular transport. Building on pioneering work in chaotropic delivery, PINCLUS introduces a novel strategy using boron clusters as protein nanocarriers to enable precise modification across diverse protein types and ensures traceless release of the native protein upon internalization, preserving biological function.

Through interdisciplinary training in chemistry, biology, and biophysics, and supported by the host’s expertise in chaotropic transporters, this action will establish the first proof-of-concept for selective intracellular delivery of chaotropic protein hybrids. PINCLUS will unlock new frontiers in protein drug development and empower the applicant’s transition to scientific independence.

Topics

Who is involved

OrganisationCityCountryRole
Universidad De Santiago De CompostelaSantiago De CompostelaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI